Loading...
XNASMEDP
Market cap10bUSD
Jan 03, Last price  
339.46USD
1D
1.41%
1Q
-1.05%
Jan 2017
841.11%
IPO
1,110.63%
Name

Medpace Holdings Inc

Chart & Performance

D1W1MN
XNAS:MEDP chart
P/E
37.31
P/S
5.59
EPS
9.10
Div Yield, %
0.00%
Shrs. gr., 5y
-2.91%
Rev. gr., 5y
21.76%
Revenues
1.89b
+29.17%
272,890,000290,041,000359,059,000421,582,000436,152,000704,589,000860,969,000925,925,0001,142,377,0001,459,996,0001,885,842,000
Net income
283m
+15.33%
24,844,000-15,572,000-8,673,00013,392,00039,032,00072,894,000100,164,000144,925,000181,390,000245,211,000282,810,000
CFO
433m
+11.68%
98,142,00075,202,00084,117,00091,732,00097,385,000156,584,000201,867,000258,676,000263,327,000388,050,000433,374,000
Earnings
Feb 10, 2025

Profile

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
URL
https://investor.medpace.com/
IPO date
Aug 11, 2016
Employees
5,600
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,885,842
29.17%
1,459,996
27.80%
Cost of revenue
1,522,689
1,158,958
Unusual Expense (Income)
NOPBT
363,153
301,038
NOPBT Margin
19.26%
20.62%
Operating Taxes
52,872
37,492
Tax Rate
14.56%
12.45%
NOPAT
310,281
263,546
Net income
282,810
15.33%
245,211
35.18%
Dividends
Dividend yield
Proceeds from repurchase of equity
(144,020)
(825,775)
BB yield
1.48%
11.55%
Debt
Debt current
50,000
Long-term debt
284,244
277,734
Deferred revenue
Other long-term liabilities
28,221
22,701
Net debt
38,795
299,469
Cash flow
Cash from operating activities
433,374
388,050
CAPEX
(36,648)
(36,879)
Cash from investing activities
(34,629)
(38,742)
Cash from financing activities
(182,642)
(775,775)
FCF
205,603
656,848
Balance
Cash
245,449
28,265
Long term investments
Excess cash
151,157
Stockholders' equity
(231,409)
(371,910)
Invested Capital
960,702
969,865
ROIC
32.14%
26.35%
ROCE
49.63%
50.25%
EV
Common stock shares outstanding
31,841
33,671
Price
306.53
44.31%
212.41
-2.40%
Market cap
9,760,222
36.47%
7,152,057
-12.83%
EV
9,799,017
7,451,526
EBITDA
389,481
323,379
EV/EBITDA
25.16
23.04
Interest
488
2,905
Interest/NOPBT
0.13%
0.96%